<li>amobarbital<p>amobarbital will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ampicillin<p>pantoprazole will decrease the level or effect of ampicillin by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>axitinib<p>pantoprazole will increase the level or effect of axitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bortezomib<p>bortezomib will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>pantoprazole decreases levels of bosutinib by Other (see comment). Use Caution/Monitor. 
Comment: PPIs may decrease bosutinib concentration by ~45%; bosutinib displays pH-dependent solubility.</p></li><li>budesonide<p>pantoprazole decreases effects of budesonide by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Enteric-coated budesonide dissolves at pH &gt;5.5. Also, dissolution of extended-release budesonide tablets is pH dependent. Coadministration with drugs that increase gastric pH may cause these budesonide products to prematurely dissolve, and possibly affect release properties and absorption of the drug in the duodenum.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>carbonyl iron<p>pantoprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ceritinib<p>pantoprazole increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>pantoprazole will decrease the level or effect of ceritinib by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely.</p></li><li>cilostazol<p>pantoprazole increases toxicity of cilostazol by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider decreasing cilostazol dose; moderate CYP2C19 inhibitors may increase  serum levels of 3,4-dehydrocilostazol (active metabolite).</p></li><li>clopidogrel<p>pantoprazole decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to the active clopidogrel metabolite. Clopidogrel is metabolized in part by CYP2C19. Pantoprazole prescribing information state that coadministration with clopidogrel had no clinically important effect on exposure to clopidogrel active metabolite; no dose adjustment of clopidogrel is required .</p></li><li>crizotinib<p>pantoprazole decreases levels of crizotinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that elevate the gastric pH may decrease the solubility of crizotinib and subsequently reduce its bioavailability. However, no formal studies have been conducted. .</p></li><li>cyclosporine<p>cyclosporine, pantoprazole.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.<span><br><br></span>pantoprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>dabigatran<p>pantoprazole will increase the level or effect of dabigatran by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Atrial fibrillation: Avoid coadministering dabigatran with P-gp inhibitors if CrCl &lt;30 mL/min.  DVT/PE treatment: Avoid coadministering dabigatran with P-gp inhibitors if CrCl &lt;50 mL/min</p></li><li>dabrafenib<p>pantoprazole will decrease the level or effect of dabrafenib by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability<span><br><br></span>dabrafenib will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Use alternative if available</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of pantoprazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dextroamphetamine<p>pantoprazole, dextroamphetamine. Other (see comment). Use Caution/Monitor. 
Comment: Reduced gastric acidity caused by proton pump inhibitors decreases time to Tmax for amphetamine and dextroamphetamine. AUC was unaffected. .</p></li><li>digoxin<p>pantoprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>eliglustat<p>eliglustat increases effects of pantoprazole by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>ferric gluconate<p>pantoprazole will decrease the level or effect of ferric gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous fumarate<p>pantoprazole will decrease the level or effect of ferrous fumarate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous gluconate<p>pantoprazole will decrease the level or effect of ferrous gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous sulfate<p>pantoprazole will decrease the level or effect of ferrous sulfate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>fosamprenavir<p>pantoprazole will decrease the level or effect of fosamprenavir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>gefitinib<p>pantoprazole decreases levels of gefitinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Avoid coadministration of gefitinib with PPIs if possible. If treatment with a PPI is required, separate gefitinib and PPI doses by 12 hr.</p></li><li>iron dextran complex<p>pantoprazole will decrease the level or effect of iron dextran complex by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>iron sucrose<p>pantoprazole will decrease the level or effect of iron sucrose by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ivacaftor<p>pantoprazole will increase the level or effect of ivacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose adjustment may be necessary</p></li><li>ledipasvir/sofosbuvir<p>pantoprazole decreases levels of ledipasvir/sofosbuvir by Other (see comment). Use Caution/Monitor. 
Comment: Ledipasvir solubility decreases as pH increases; drugs that increase gastric pH are expected to decrease levels of ledipasvir; proton-pump inhibitor doses comparable to omeprazole &lt;20 mg can be administered simultaneously with ledipasvir/sofosbuvir under fasted conditions.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, pantoprazole. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .<span><br><br></span>lumacaftor/ivacaftor will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lumacaftor/ivacaftor is a strong CYP3A4 inhibitor and also has the potential to induce CYP2C19 and both induce and inhibitor P-gp.</p></li><li>methotrexate<p>pantoprazole increases levels of methotrexate by decreasing renal clearance. Use Caution/Monitor. Increased risk of toxicity with higher doses.</p></li><li>mycophenolate<p>pantoprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Potential interaction applies to the prodrug mycophenolate mofetil conversion to active mycophenolic acid. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction.</p></li><li>nintedanib<p>pantoprazole increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of pantoprazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>polysaccharide iron<p>pantoprazole will decrease the level or effect of polysaccharide iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ponatinib<p>ponatinib increases levels of pantoprazole by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>posaconazole<p>pantoprazole will decrease the level or effect of posaconazole by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>regorafenib<p>regorafenib will increase the level or effect of pantoprazole by  Other (see comment). Modify Therapy/Monitor Closely. Regorafenib likely inhibits BCRP (ABCG2) transport. Coadministration with a BCRP substrate may increase systemic exposure to the substrate and related toxicity.</p></li><li>rifampin<p>rifampin will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>rifaximin<p>pantoprazole increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rose hips<p>pantoprazole will decrease the level or effect of rose hips by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>saquinavir<p>pantoprazole will decrease the level or effect of saquinavir by  unknown mechanism. Use Caution/Monitor. Potential for increased toxicity.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.<span><br><br></span>secobarbital will decrease the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>tacrolimus<p>pantoprazole will increase the level or effect of tacrolimus by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Concomitant administration may increase tacrolimus whole blood concentrations, particularly in intermediate or poor metabolizers of CYP2C19</p></li><li>telithromycin<p>telithromycin, pantoprazole.
Either decreases effects of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>pantoprazole, telithromycin.
Either decreases effects of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>telithromycin increases levels of pantoprazole by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>theophylline<p>pantoprazole increases toxicity of theophylline by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of proton pump inhibitors can cause hypochlorhydria, which in turn causes peristalsis in small intestine to increase and peristalsis in the proximal colon to decrease; monitor for toxicity.</p></li><li>vismodegib<p>pantoprazole will decrease the level or effect of vismodegib by  Other (see comment). Use Caution/Monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown<span><br><br></span>pantoprazole will increase the level or effect of vismodegib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Vismodegib is a substrate of efflux transporter P-glycoprotein (P-gp); coadministration with P-gp inhibitors increase vismodegib systemic exposure</p></li><li>voriconazole<p>voriconazole will increase the level or effect of pantoprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.<span><br><br></span>voriconazole will increase the level or effect of pantoprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li>